Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.

Masaya TachibanaKyriakos P PapadopoulosJohn H StricklerIgor PuzanovRoohi GajeeYibin WangHamim Zahir

Published in: British journal of clinical pharmacology (2017)

The data suggest that tivantinib 360 mg twice daily has either a minimal or no effect on the pharmacokinetics of probe drugs for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 substrates, and decreases the systemic exposure of P-glycoprotein substrates when administered with tivantinib.

Keyphrases

living cells
small molecule
drug induced
electronic health record
physical activity
quantum dots
big data
single molecule
machine learning
risk assessment
human health
nucleic acid